Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1295Pancreatic Neoplasms 818Carcinoma, Hepatocellular 782Stomach Neoplasms 753Rectal Neoplasms 565Esophageal Neoplasms 452Colonic Neoplasms 414Esophageal Squamous Cell Carcinoma 277Neoplasm Metastasis 263Cholangiocarcinoma 251Liver Neoplasms 219Neoplasms 200Biliary Tract Neoplasms 179Adenocarcinoma Of Esophagus 139Gastrointestinal Stromal Tumors 108Gallbladder Neoplasms 96Adenocarcinoma 94Breast Neoplasms 91Gastrointestinal Neoplasms 89Carcinoma, Non-Small-Cell Lung 87Bile Duct Neoplasms 69Sarcoma 67Lung Neoplasms 64Ovarian Neoplasms 60Anus Neoplasms 59Melanoma 54Uterine Cervical Neoplasms 52Carcinoma 48Digestive System Neoplasms 45Prostatic Neoplasms 40

Interventions

regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bile Duct Diseases × Gastrointestinal × Clear all
NCT02115542 2021-10-12

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
39 enrolled 11 charts
Gastrointestinal

Bile Duct Diseases, Bile Duct Neoplasms, Carcinoma, Gallbladder Diseases, Gallbladder Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡